Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western pharmaceutical companies and Chinese biotechs, multiple research firms suggest.

Large pharma companies have in-licensed nearly a third of their external molecules from Chinese